US Bone Metastasis Market

ID: MRFR/Pharma/17375-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026
US Bone Metastasis Market Research Report By Type (Osteolytic, Osteoblastic, Mixed) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Life Sciences, BY Type (USD Billion)
      1. 4.1.1 osteolytic bone metastasis
      2. 4.1.2 osteoblastic bone metastasis
      3. 4.1.3 mixed bone metastasis
      4. 4.1.4 others
    2. 4.2 Life Sciences, BY Diagnosis (USD Billion)
      1. 4.2.1 biopsy
      2. 4.2.2 blood test
      3. 4.2.3 imaging
      4. 4.2.4 others
    3. 4.3 Life Sciences, BY Treatment (USD Billion)
      1. 4.3.1 medical therapies
      2. 4.3.2 surgery
      3. 4.3.3 medication
      4. 4.3.4 others
    4. 4.4 Life Sciences, BY End-User (USD Billion)
      1. 4.4.1 hospitals and clinics
      2. 4.4.2 diagnostic centers
      3. 4.4.3 pharmacies
      4. 4.4.4 ambulatory surgical centers
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Life Sciences
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Amgen (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Novartis (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Roche (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Eli Lilly (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck & Co. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Bayer (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Sanofi (FR)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 US MARKET ANALYSIS BY TREATMENT
    5. 6.5 US MARKET ANALYSIS BY END-USER
    6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
    9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
    11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
    12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
    13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 LIFE SCIENCES, BY DIAGNOSIS, 2024 (% SHARE)
    15. 6.15 LIFE SCIENCES, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
    16. 6.16 LIFE SCIENCES, BY TREATMENT, 2024 (% SHARE)
    17. 6.17 LIFE SCIENCES, BY TREATMENT, 2024 TO 2035 (USD Billion)
    18. 6.18 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
    19. 6.19 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Billion)
      4. 7.2.4 BY END-USER, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Life Sciences Market Segmentation

Life Sciences By Type (USD Billion, 2025-2035)

  • osteolytic bone metastasis
  • osteoblastic bone metastasis
  • mixed bone metastasis
  • others

Life Sciences By Diagnosis (USD Billion, 2025-2035)

  • biopsy
  • blood test
  • imaging
  • others

Life Sciences By Treatment (USD Billion, 2025-2035)

  • medical therapies
  • surgery
  • medication
  • others

Life Sciences By End-User (USD Billion, 2025-2035)

  • hospitals and clinics
  • diagnostic centers
  • pharmacies
  • ambulatory surgical centers